BiotechTube

Dexamethasone ophthalmic suspension (OCS-01) + Vehicle

Phase 2/3Active
0 watching 0 views this week📈 Rising
60
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetic Macular Edema

Conditions

Diabetic Macular Edema

Trial Timeline

Oct 19, 2021 → Apr 1, 2026

NCT ID
NCT05066997

About Dexamethasone ophthalmic suspension (OCS-01) + Vehicle

Dexamethasone ophthalmic suspension (OCS-01) + Vehicle is a phase 2/3 stage product being developed by Oculis Holding AG for Diabetic Macular Edema. The current trial status is active. This product is registered under clinical trial identifier NCT05066997. Target conditions include Diabetic Macular Edema.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (2)

NCT IDPhaseStatus
NCT06172257Phase 3Active
NCT05066997Phase 2/3Active

Competing Products

20 competing products in Diabetic Macular Edema

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
44
CHF6467 activeComac MedicalPhase 1/2
33
Ruboxistaurin mesylateEli LillyPhase 3
77
KVD001 InjectionKalVista PharmaceuticalsPhase 2
47
KVD001 InjectionKalVista PharmaceuticalsPhase 1
28
Baricitinib + PlaceboEli LillyPhase 2
52
LY3857210 + PlaceboEli LillyPhase 2
52
UBX1325Unity BiotechnologyPhase 2
44
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
44
UBX1325Unity BiotechnologyPhase 1
25
CT-P42 + EyleaCelltrionPhase 3
77
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
85
Anplag(Sarpogrelate) + PlaceboYuhanApproved
85
CS-3150 + placeboDaiichi SankyoPhase 2
52
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
52
olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3
77
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
Beraprost sodiumAstellas PharmaPre-clinical
23

Other Products from Oculis Holding AG

OCS-01 + VehiclePhase 3
72
Dexamethasone Ophthalmic SuspensionPhase 3
72
Dexamethasone ophthalmic suspension (OCS-01) + VehiclePhase 3
72
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + PlaceboPhase 2
47
OCS-01Phase 2
47